Nanoliposome Containing Cyclosporine a Reduced Neuroinflammation Responses and Improved Neurological Activities in Cerebral Ischemia/Reperfusion in Rat Publisher Pubmed



Partoazar A¹ ; Nasoohi S² ; Rezayat SM³ ; Gilani K⁴ ; Mehr SE³ ; Amani A⁵ ; Rahimi N¹ ; Dehpour AR^{1, 3} Show Affiliations
Source: Fundamental and Clinical Pharmacology Published:2017

Abstract

Cyclosporine A (CsA) is known as a neuroprotective agent against cerebral ischemia/reperfusion (I/R) in animal models. However, the significant therapeutic effects of CsA have been observed in high systemic doses or manipulating the blood–brain barrier, resulting in systemic side effects and toxicity. As the liposome nanocarriers have been developed for efficient delivery of peptide and proteins, liposomal CsA (Lipo-CsA) could improve cerebral (I/R) injuries. In this study, the liposomal CsA formulation (CsA at dose of 2.5 mg/kg) was prepared to assess the brain injury outcomes in 90 min middle cerebral artery occlusion (MCAO) stroke model followed by 48 h reperfusion in treating rats. Five minutes after induction of cerebral ischemia in rats, intravenous (iv) administration of Lipo-CsA significantly (P < 0.001) recovered the infarct size, the brain edema, and the neurological activities compared to corresponding control groups following 48 h I/R. In addition, after 48 h cerebral I/R, Lipo-CsA potentially (P < 0.001) inhibited the inflammation responses including MPO activity and tumor necrosis factor-alpha level in comparison to other groups. In conclusion, the results indicate that the low dose of CsA in liposomal formulation is more effective compared to higher dose of free form of CsA in treatment of ischemic brain in rats. © 2016 Societe Francaise de Pharmacologie et de Therapeutique